Elarofiban (diTFA)

• Description:

  Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research[1][2].

• UNSPSC:

  12352005

• Target:

  Integrin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/elarofiban-ditfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (N[C@H] (C1=CN=CC=C1) CC (O) =O) [C@H]2CN (CCC2) C (CCC3CCNCC3) =O.OC (C (F) (F) F) =O.OC (C (F) (F) F) =O

• Molecular Formula:

  C26H34F6N4O8

• Molecular Weight:

  644.56

• References & Citations:

  [1]Judith H. Cohen, et al. A Practical Synthesis of the Platelet Fibrinogen Antagonist, Elarofiban. Organic Process Research & Development 2003, 7, 866-872.|[2]De Corte BL, et al., Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14 (20) :5227-32.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  198958-89-3